[89Zr]Zr-DBN labeled cardiopoietic stem cells proficient for heart failure
| Autor: | Andre Terzic, Ryoung-Hoon Jeon, Tyra A. Witt, Jonathan J. Nesbitt, Raman Deep Singh, Mukesh K. Pandey, Soulmaz Boroumand, Ruben J. Crespo-Diaz, Ribu Goyal, Mark Li, Tina M. Gunderson, Matthew L. Hillestad, Atta Behfar, Timothy R. DeGrado, Aditya Bansal, Nicholas R. Schmit, Satsuki Yamada |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cancer Research
Ejection fraction medicine.diagnostic_test business.industry Cell medicine.disease Regenerative medicine 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Positron emission tomography 030220 oncology & carcinogenesis Heart failure medicine Cancer research Molecular Medicine Radiology Nuclear Medicine and imaging Myocardial infarction Stem cell Molecular imaging business |
| Zdroj: | Nuclear Medicine and Biology. :23-30 |
| ISSN: | 0969-8051 |
| DOI: | 10.1016/j.nucmedbio.2020.09.001 |
| Popis: | Introduction Radiolabeling of stem cells with a positron emitting radioisotope represents a major advancement in regenerative biotherapy enabling non-invasive imaging. To assess the value of such an approach in a clinically relevant scenario, the tolerability and therapeutic aptitude of [89Zr]zirconium-p-isothiocyanatobenzyl-desferrioxamine ([89Zr]Zr-DBN) labeled human cardiopoietic stem cells (CPs) were evaluated in a model of ischemic heart failure. Methods and results [89Zr]Zr-DBN based radiolabeling of human CPs yielded [89Zr]Zr-DBN-CPs with radioactivity yield of 0.70 ± 0.20 MBq/106 cells and excellent label stability. Compared to unlabeled cell counterparts, [89Zr]Zr-DBN-CPs maintained morphology, viability, and proliferation capacity with characteristic expression of mesodermal and pro-cardiogenic transcription factors defining the cardiopoietic phenotype. Administered in chronically infarcted murine hearts, [89Zr]Zr-DBN-CPs salvaged cardiac pump failure, documented by improved left ventricular ejection fraction not inferior to unlabeled CPs and notably superior to infarcted hearts without cell treatment. Conclusion The present study establishes that [89Zr]Zr-DBN labeling does not compromise stem cell identity or efficacy in the setting of heart failure, offering a non-invasive molecular imaging platform to monitor regenerative biotherapeutics post-transplantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect